WHAT'S KNOWN ON THIS SUBJECT: Primary hypertension is a growing concern in adolescents due to its association with the obesity epidemic. Recent studies have examined underdetection and underdiagnosis of hypertension in adolescents but medical management of primary hypertension in adolescents is not welldescribed.
METHODS:
We identified adolescents with primary hypertension by International Classification of Diseases, Ninth Revision codes and looked at prescription patterns chronologically for antihypertensive drug class prescribed and the specialty of prescribing physician. We also examined patient demographics and presence of obesity-related comorbidities.
RESULTS: During 2003-2008
, there were 4296 adolescents with primary hypertension (HTN); 66% were boys; 73% were aged 11 to 14 years; 53% were black, 41% white, and 4% Hispanic; and 48% had obesity-related comorbidity. Twenty-three percent (977) received antihypertensive prescription. White subjects (odds ratio [OR]: 1.61; confidence interval [CI]: 1.39-1.88), older adolescents ($15 years, OR: 2.11; CI: 1.79-2.48), and those with comorbidity (OR: 1.57; CI: 1.36-1.82) were more likely to receive antihypertensive prescriptions controlling for gender and years of Medicaid eligibility in logistic regression. Angiotensin converting enzyme inhibitors were the most frequently prescribed monotherapy. Nearly two-thirds of adolescents received prescriptions from adult primary care physicians (PCPs) only. More than one-quarter of adolescents who received a prescription received combination therapy, which was most often prescribed by adult PCPs.
CONCLUSIONS: Adult PCPs were the leading prescribers of antihypertensives for adolescents with primary HTN. Race differences exist in physicians' prescribing of antihypertensives to adolescents with primary HTN. The choice of antihypertensives by physicians of different specialties warrants additional study to understand the underlying rationale for treatment decisions and to determine treatment effectiveness. Pediatrics 2012;129:e1-e8 There is growing concern about elevated blood pressure (BP) and hypertension (HTN) in adolescents because of its association with the obesity epidemic, which is estimated as affecting one-third of American adolescents. [1] [2] [3] Moreover, HTN in adults is a known risk factor for cardiovascular disease (CVD), one of the leading causes of morbidity and mortality in American adults. 4 Recent studies have examined issues of underdetection and underdiagnosis of HTN in adolescents. 5, 6 However, current medical management of primary HTN in adolescents has not been well described.
Pediatric guidelines (2004) recommend initiating antihypertensive drug therapy in adolescents who have persistent HTN despite lifestyle modifications, using monotherapy from any of the 5 common antihypertensive drug classes: angiotensin converting enzyme inhibitors (ACEs), angiotensin receptor blockers (ARBs), b-blockers (BBs), calcium channel blockers, and diuretics (DIUs); importantly, there is no prioritization of drug choice. 7 Guidelines also recommend consideration of combination drugs if the desired BP goal is not achieved on monotherapy. It is unknown which antihypertensive medications are prescribed for treatment of primary HTN in adolescents and whether pharmacotherapy varies by the specialty of prescribing physician and/or patient characteristics such as demographics and presence of comorbidities.
The purpose of this study was to describe the use of antihypertensive pharmacotherapy to treat primary HTN in adolescents and the associated physician and patient characteristics. Our assumption was that subspecialty physicians, such as pediatric cardiologists and nephrologists, would most frequently prescribe antihypertensive medications to adolescents with primary HTN and that adolescents with comorbidities, such as obesity and diabetes would more likely receive antihypertensive therapy compared with those without comorbidity.
METHODS

Study Design
We 
Study Sample Characteristics
For the 4296 adolescents who met eligibility criteria, two-thirds were boys; 73% were aged 11 to 14 years at start of Medicaid eligibility; and 53% were black, 41% white, and 4% Hispanic ( Table 1 ). The majority of our study sample (n = 3806) had a diagnosis of HTN (401.3), and 490 adolescents had elevated BP without HTN (796.2) with no difference in demographics. Our sample demographics (n = 4296) were also similar to the Medicaid population in general with the exception of gender; one-third of our sample were girls, whereas gender was more evenly distributed in the general Medicaid population. Nearly half had an obesity-related comorbidity (48%). One-third of adolescents had 6 years of Medicaid eligibility, with 80% enrolled during the first year (2003) of the study period (Table 1) .
During the study period, 23% of adolescents in our sample (n = 977) received at least 1 antihypertensive prescription. A quarter of the 3806 with HTN diagnosis (401.3) received antihypertensive Table 2 . Older and white adolescents were more likely than younger and black adolescents to receive an antihypertensive prescription. Adolescents with obesity comorbidity also were more likely to receive an antihypertensive prescription.
Mean and median antihypertensive prescriptions filled per year of Medicaid eligibility were 2.4 and 1.2, respectively. This did not vary significantly by gender; however, white subjects (mean 2.9, median 1.4) and older adolescents (mean 3.3, median 1.5) had higher mean and median prescriptions per year of eligibility compared with black subjects (mean 1.9, median 0.8) and younger adolescents (mean 1.9, median 0.8; P , .0001).
Antihypertensive Prescriptions for Adolescents With Primary HTN (n = 977)
Overall, mean and median age at first antihypertensive prescription was similar at 16.9 and 17 years, respectively, and did not vary significantly by gender, race, or presence of obesity-related comorbidity. Among adolescents who received antihypertensive prescription, 86% (n = 839) initially received monotherapy; 72% (n = 701) continued with monotherapy only during the study period, with ACE as the most frequently prescribed drug class (Table 3) . Twelve percent of the monotherapy-only group was switched from the initial antihypertensive monotherapy to a different monotherapy drug class during the study period, most often from diuretics and BB to ACE.
Combination antihypertensive therapy was prescribed at some point in the study period for 28% (n = 276) of adolescents who received any antihypertensive prescription. Of the 276 adolescents who ever received combination therapy, 50% (n = 138) had combination antihypertensives as the first prescription identified during the study period, 30% (n = 84) received combination therapy within the first year of receiving monotherapy, and 20% (n = 54) received combination therapy $1 to 6 years after receiving monotherapy. The 3 most commonly prescribed drug combinations were ACE-DIU, DIU-DIU, and BB-DIU combinations. Among adolescents who ever received combination therapy, 68% (n = 188) were prescribed 1-pill combination drugs (Table 3) .
Physician Specialty (n = 977)
Nearly two-thirds of adolescents with primary HTN with antihypertensive prescription received prescriptions from adult PCPs only (Table 3 ). Ten percent of adolescents received their antihypertensive prescription only from Specs, and 5% received their antihypertensive prescription only from pediatric PCPs.
Adult PCPs (62%) were also leading prescribers of combination antihypertensives, whereas Specs (7%) and pediatric PCPs (3%) prescribed fewer combination antihypertensives (Table 3) . Adolescents who received antihypertensive prescriptions from physicians of multiple specialties during the study period were more likely to receive combination therapy versus monotherapy (42% from both PCPs and Specs, n = 57; 34% from both adult PCPs and pediatric PCPs, n = 11) compared with those receiving prescriptions from adult PCPs only (28%, n = 172), Specs only (20%, n = 19), and pediatric PCPs only (16%, n = 7; P , .0001; Table 3 ).
Among the subset of adolescents receiving combination therapy, those who received prescriptions from physicians of multiple specialties during the study period (both adult PCP + pediatric PCP and both PCP + Spec groups) were also more likely to receive combination therapy as multiple drugs than as 1 pill compared with those receiving combination therapy from physicians of single specialty with the exception of unknowns (Table 3) . Prescription of combination therapy as 1 pill versus multiple drugs did not vary significantly by race, age, and gender.
Multivariate Logistic Regression Analysis
Among all adolescents with primary HTN, receipt of antihypertensive prescriptions was significantly associated with age, race, and presence of obesityrelated comorbidity in our multivariate logistic regression model (Table 4) . Controlling for patient gender and years of Medicaid eligibility, older adolescents, those with obesity-related comorbidities, and white subjects were more likely to receive antihypertensive prescriptions compared with younger adolescents, those without obesity comorbidity, and black subjects.
Among the subset of adolescents who received antihypertensive prescriptions, receipt of combination therapy was significantly associated with age, gender, race, and prescribing physician specialty in our multivariate logistic regression model (Table 5) . Controlling for obesity comorbidity and years of Medicaid eligibility, older adolescents, girls, black subjects, and adolescents who received prescriptions from both PCPs and Specs were more likely to receive combination therapy compared with younger adolescents, boys, white subjects, and adolescents who received prescriptions only from Specs.
DISCUSSION
Our study describes for the first time the proportion of adolescents with primary HTN who receive antihypertensive prescriptions over a multiyear period and demographic characteristics associated with receipt of antihypertensive prescriptions. Additionally, our study provides the first look at patterns of antihypertensive prescribing for adolescents with primary HTN including the use of monotherapy versus combination therapy by physicians of different specialties and factors associated with receipt of combination antihypertensive therapy.
In our study, white adolescents were significantly more likely to receive antihypertensive prescriptions compared with black subjects when controlling for obesity-related comorbidity, patient age, and gender, as well as years of Medicaid eligibility. Previous studies of US adults have documented race disparities in HTN prevalence with nonHispanic black subjects having higher risk for HTN, CVD, and stroke compared with non-Hispanic white subjects and Mexican-American subjects. 8 Our study suggests that race differences exist in physicians' prescribing of antihypertensives to adolescents with primary HTN. Importantly, we also found that black adolescents were more likely to receive combination therapy compared with white subjects when controlling for other patient characteristics and specialty of prescribing physician.
Taken together, these findings may reflect potential undertreatment or delay in treatment of HTN in black subjects. Increased use of combination therapy in black subjects may also reflect more aggressive BP control given that black adolescents with primary HTN have 
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higher risk of CVD compared with nonblack adolescents. 9 Previous studies of adults with HTN have shown black subjects to be less responsive to monotherapy and thus often requiring treatment with drugs from 2 or more antihypertensive drug classes. 10 Additional study of physician decision making, as well as clinical outcomes, is warranted to better understand the racial patterns observed in this study.
Our study also found that older adolescents and those with obesity-related comorbidities were more likely to receive antihypertensive prescriptions compared with younger adolescents and those without comorbidity when controlling for patient gender and race. Older adolescents were also more likely to receive combination therapy. This is consistent with previous work 11 and with clinical experience; older adolescents are more likely to have longer duration of disease, higher severity of disease, and/or episodes of treatment failures. Moreover, guidelines recommend pharmacotherapy to treat HTN in adolescents with comorbid conditions; thus, our findings are consistent with treatment recommendations according to national guidelines. 7 Antihypertensive medications were prescribed most frequently by adult PCPs in our study. Elevated BP values indicating hypertensive range for adolescents (eg, 122/80 for a 12-year-old boy at the lowest height quartile) begin to resemble pre-HTN (120/80) for adults, indicating increased risk of heart disease and stroke. 4, 7, 12 13 and it seems plausible that lack of familiarity with antihypertensive medications may play a role in this low rate. In addition, we have previously described pediatric cardiologists' and nephrologists' reluctance to initiate recommended antihypertensive pharmacotherapy in children with primary HTN. 14 Additional studies are needed to elucidate the underlying factors related to prescribing of antihypertensive pharmacotherapy in adolescents with primary HTN.
The use of combination antihypertensive pharmacotherapy suggests increased severity of illnesswhere optimal BP control cannot be achieved on monotherapy. In our study, more than a quarter of Medicaid adolescents with primary HTN who received antihypertensive prescriptions were prescribed combination therapy. Importantly, we found that adolescents receiving combination therapy from physicians of multiple specialties during the study period received it more often in the form of multiple drugs that raise questions of medical comanagement and whether the use of multiple antihypertensives is coordinated between prescribers of different specialties. One rationale for prescribing multiple-drug combination therapy is cost; 4 of 5 recommended monotherapy drug classes have generic options available, whereas combination pills are relatively more new without generic options. 15 However, it is unknown whether there are differences in patient outcomes related to drug safety and efficacy using antihypertensive combination therapy prescribed as combination pill versus multiple drugs in adolescents with HTN. Further study is needed to evaluate treatment decisions and patient outcomes regarding the use and choice of different forms of combination therapy (1 pill vs multiple drugs) in adolescents with primary HTN by physicians of different specialty training.
LIMITATIONS
Our findings should be interpreted with these limitations. First, our study population was adolescents enrolled in the Michigan Medicaid program, which has potential implications for generalizability of our results. Second, limitations of pharmacy claims analysis suggest prescription claims that were filled, which may potentially differ from utilization. Third, we examined prescription claims at the level of drug class, not individual drugs. We were 
